Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.
Clicks: 139
ID: 119378
1993
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
139 views
29 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #95 of 105 articles by views in Antimicrobial agents and chemotherapy
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
We performed a randomized, controlled trial of intravenous immune globulin (respiratory syncytial virus [RSV] neutralizing [Nt] antibody titer of 1:950 in 5% solution) to evaluate protection against RSV-induced disease over two respiratory virus seasons. ...
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (32 words).
Try re-searching for a better abstract.
| Reference Key |
snydman1993antimicrobialcontrolled
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | H C Meissner, D R Fulton, J R Groothuis, R L Geggel, G R Marx, V G Hemming, T Hougen, D R Snydman;H C Meissner;D R Fulton;J R Groothuis;R L Geggel;G R Marx;V G Hemming;T Hougen;D R Snydman; |
| Journal | Antimicrobial agents and chemotherapy |
| Year | 1993 |
| DOI |
10.1128/aac.37.8.1655
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.